Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Oct 2015: Trial registered, NCT02567435
  2. 1 Jun 2016: Trial started, NCT02567435

The trials

NCT02567435: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

State
Under way
Phase
Phase 3
People
325 taking part
Started
1 Jun 2016
Primary completion
30 Jun 2023
Arms
Regimen A (VAC/VI)
Results
Posted on the registry
  1. 5 Oct 2015: Trial registered
  2. 1 Jun 2016: Trial started
  3. 1 Oct 2024: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Event-free Survival (EFS)

Primary outcome · Number, Percentage of participants · Up to 3 years from study entry

GroupAnalysedValue
Regimen A (VAC/VI)14864.80 (95% Confidence Interval 55.5 to 74.1)
Regimen B (VAC/VI/Temsirolimus)14966.80 (95% Confidence Interval 57.5 to 76.2)
  • p = 0.44, Log Rank (superiority test); 3-Year EFS 65.8. Posted for: Regimen A (VAC/VI), Regimen B (VAC/VI/Temsirolimus)

Overall Survival (OS)

Secondary outcome · Number, Percentage of participants · Up to 3 years from study entry

GroupAnalysedValue
Regimen A (VAC/VI)14878.70 (95% Confidence Interval 70.9 to 86.4)
Regimen B (VAC/VI/Temsirolimus)14977.80 (95% Confidence Interval 69.7 to 85.9)
  • p = 0.56, Log Rank (superiority test); 3-Year OS 78.2. Posted for: Regimen A (VAC/VI), Regimen B (VAC/VI/Temsirolimus)

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.